The polyepitope approach to DNA vaccination

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 1, 1999, Pages 10-15

  Smith, Steven Gerard ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA VACCINE; EPITOPE;

AMINO ACID SEQUENCE; CANCER; CYTOTOXICITY; DRUG SAFETY; GENE CONSTRUCT; HLA SYSTEM; IMMUNITY; INFECTION; REVIEW; T LYMPHOCYTE SUBPOPULATION; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; COMMUNICABLE DISEASES; EPITOPES; HUMANS; MICE; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0032932811     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-Infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 154:3961-3968.
2. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Mad (1993) 178:489-495.
3. Boon T, Van Der Bruggen P: Human tumor antigens recognized by T lymphocytes. J Exp Med (1996) 183:725-729.
4. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA: Immunization against epitopes in the human melanoma antigen gp100 following patient Immunization with synthetic peptides. Cancer Res (1996) 56:4749-4757. The Induction of CTLs to melanoma antigen-derived peptide epitopes in vitro.
5. Hu X, Chakraborty NG, Spom JR, Kurtzman SH, Ergin MT, Mukherji B: Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res (1996) 56:2479-2483.
6. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinellin, Bourlond A, Vanwijck R, Humblet Y: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [letter]. Int J Cancer (1995) 63:883-885.
7. Jaeger E, Bemhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedom M, Knuth A: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int J Cancer (1996) 66:162-169.
8. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM: Enhancement of cellular Immunity in melanoma patients Immunized with a peptide from MART-1/Melan A. Cancer J Sci Am (1997) 3:37-44.
9. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spless PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 4:321-327.
10. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P: Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol (1998) 160:1750-1758.
11. Tourdot S, Oukka M, Manuguerra JC, Magafa V, Vergnon I, Riche N, Bruley-Rosset M, Cordopatis P, Kosmatopoulos K: Chimeric peptides: A new approach to enhancing the Immunogenicity of peptides with low MHC class I affinity: Application In antiviral vaccination. J Immunol (1997) 159:2391-2398.
12. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E: The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol (1998) 59:1-14.
13. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4:328-332.
14. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med (1994) 179:1109-1118.
15. Tuting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CL Jr, Wagner SN, Van Der Bruggen P, Baar J, Lotze MT, Storkus WJ: Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1- biasing cytokines IL-12 and IFN-alpha. J Immunol (1998) 160:1139-1147.
16. Hsu SC, Obeid OE, Collins M, Iqbal M, Chargelegue D, Steward MW: Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: involvement of IFN-gamma. Int Immunol (1998) 10:1441-1447.
17. Pasquini S, Xiang Z, Wang Y, He Z, Deng H, Blaszczyk-Thurin M, Ertl HC: Cytokines and costimulatory molecules as genetic adjuvants. Immunol Cell Biol (1997) 75:397-401.
18. Del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH: Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell (1991) 66:1145-1153.
19. Thomson SA, Khanna R, Gardner J, Burrows SR, Coupar B, Moss DJ, Suhrbler A: Minimal epitopes expressed in a recombinant polyepltope protein are processed and presented to CD8+ cytotoxic T cells: Implications for vaccine design. Proc Natl Acad Sci USA (1995) 92:5845-5849.
20. Thomson SA, Elliott SL, Sherritt MA, Sproat KW, Coupar BE, Scalzo AA, Forbes CA, Ladhams AM, Mo XY, Tripp RA, Doherty PC, Moss DJ, Suhrbier A: Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol (1996) 157:822-826. Results that show the induction of CTLs in mice to all epitopes of a murine polyepitope despite unnatural flanking residues.
21. Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJ, Brown LE, Suhrbier A: Delivery of multiple CD8+ cytotoxic T cell epitopes by DNA vaccination. J Immunol (1998) 160:1717-1723.
22. Toes RE, Hoeben RC, Van Der Voort EI, Ressing ME, Van Der Eb AJ, Melief CJ, Offringa R: Protective anti-tumor immunity Induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA (1997) 94:14660-14665.
23. Hanke T, Schneider J, Gilbert SC, Hill AV, McMichael A: DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice. Vaccine (1998) 16:426-435. Western blot result that Indicates not all polyepitope proteins are unstable Intracellularly.
24. Hanke T, Blanchard TJ, Schneider J, Ogg GS, Tan R, Becker M, Gilbert SC, Hill AV, Smith GL, McMichael A: immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 In mice. J Gen Virol (1998) 79:83-90.
25. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, Gilbert SC, Hill AV, Smith GL, McMichael A: Enhancement of MHC class I-restricted peptide-specific T-cell Induction by a DNA prime/MVA boost vaccination regime. Vaccine (1998) 16:439-445.
26. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kombluth RS, Richman DD, Carson DA, Raz E: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 3:849-854.
27. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC: Activation of cutaneous dendritic cells by CpG-containing ollgodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol (1998) 161:3042-3049.
28. Thomson SA, Burrows SR, Misko IS, Moss DJ, Coupar BE, Khanna R: Targeting a polyepitope protein incorporating multiple class II-restricted viral epltopes to the secretory/endocytic pathway facilitates Immune recognition by CD4+ cytotoxic T lymphocytes: A novel approach to vaccine design. J Virol (1998) 72:2246-2252. Evidence that it is possible to target helper epitopes into the secretory pathway for loading onto MHC class II molecules despite production in the cytosol.
29. Driscoll J, Brown MG, Finley D, Monaco JJ: MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature (1993) 365:262-264.
30. Wang Y, Guttoh DS, Androlewicz MJ: TAP prefers to transport melanoma antigenic peptides which are longer than the optimal T-cell epitope: Evidence for further processing in the endoplasmic reticulum. Melanoma Res (1998) 8:345-353.
31. Momburg F, Roelse J, Hammerling GJ, Neefjes JJ: Peptlde size selection by the major histocompatibility complex-encoded peptlde transporter. J Exp Mod (1994) 179:1613-1623.
32. Bergmann CC, Yao Q, Ho CK, Buckwold SL: Flanking residues alter antigenicity and immunogenicity of multiunit CTL epitopes. J Immunol (1996) 157:3242-3249.